LEXINGTON, Mass., March 24, 2020 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced unaudited, preliminary financial result estimates for the quarter ended March 31, 2020, and suspended full year2020 financial and operational guidance due to uncertainties from the impact of the novel coronavirus (COVID-19) pandemic.
The Company continues to leverage its technology and scientific expertise to aid in the COVID-19 response while prioritizing the health and safety ofits employees and customers. T2 Biosystems recently announced a licensing agreement to support development of a rapid COVID-19 test, developed bythe Center of Discovery and Innovation (CDI) at Hackensack Meridian Health, enabling a larger role in the pandemic response.
The licensed coronavirus assay has been used by healthcare professionals within the Hackensack Meridian Health network, under the U.S. Food andDrug Administration’s Emergency Use Authorization guidance, to test and treat patients suspected of having coronavirus. T2 Biosystems intends toadapt the newly licensed COVID-19 test to run on its T2Dx® Instrument, the same instrument used for the FDA-cleared T2Bacteria® and T2Candida®Panels, allowing the detection of both coronavirus and associated secondary bacterial or fungal infections that may lead to sepsis.